New Delhi: Made-in-India neutralizes several variants of the COVID-19 vaccine, covaxin, SARS-CoV-2 and effectively works against the dual mutant strain,
the Indian Council of Medical Research (ICMR) said today.
Covaxin of Bharat Biotech has received the Emergency Use Authority (EUAs) for COVID-19 treatment in India and
many countries around the world, with another 60 in the process.
ICMR tweeted, Covaxin neutralizes covid against multiple variants of SARS-CoV-2 and also neutralizes double mutant strains.
Also Read: Before the May 1 KVV-19 vaccination campaign, the Serum Institute shared the price of ‘Covisheild’, see rates here
The ICMR-National Institute of Virology has successfully isolated and cultured several forms of concern for the SARS-CoV-2 virus:
B.1.1.7 (UK version), B.1.1.28 (Brazilian version) and B.1.351 ( South Africa) vary).
The top health research officer said that ICMR-NIV has demonstrated the neutralization potential of covaxin against the UK variant and the Brazilian variant.
ICMR-NIV has been successful in isolating and promoting the double mutant strain of B.1.617 SARS-CoV-2, recently identified in some regions of India and many other countries, ICMR said.
“Covaxin has been found to effectively neutralize the double mutant strain,” it said.
Like our Facebook page
SHARE
